Jim C. Hu, MD

Highlights

1
JAMA oncology · 2024
JCJim C. Hu AJAndrew J. Vickers BEBehfar Ehdaie DADavid A. Green NANeal Arvind Patel+2 more →
PMID: 39298143PMCID: PMC11413751DOIFirst author37 citations
2
European urology · 2024
JCJim C. Hu DADavid A. Green GWGerald Wang JEJonathan E. Shoag
PMID: 38212178PMCID: PMC11976521DOIFirst author186 citations
3
The New England journal of medicine · 2020
JEJonathan E. Shoag JCJim C. Hu
PMID: 32558473PMCID: PMC7491201DOISenior author79 citations

Publications

448

Funding

21 View NIH portfolio on RePORTER ↗

Active

10 grants

PI
Cost-Effectiveness of Prostate Cancer Screening in the United States: Evaluating Current Practice and Emerging Strategies
Prostate Cancer Foundation · 2026–2029
25PILO02
PI
Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL)
National Cancer Institute · 2022–2028
R01CA259173-05
Co-I
FLOW - Flatiron Clinical Pipe™ for Optimized Workflow for Cancer Clinical Trials
American Cancer Society · 2026–2027
CTTRIA-25-1497791-01-CTTRIA
PI
Randomized Trial Comparing Transperineal vs. Transrectal MRI-targeted Prostate Biopsy
Patient-Centered Outcomes Research Institute · 2021–2027
CER-2019C2-17372
PI
Using Technology to Improve Prostate Cancer Screening Information Quality
Prevent Cancer Foundation · 2025–2027
PCF 243159-02
MPI
The Use of Confocal Microscopy for Intraoperative Real-time Margin Assessment in Prostate Cancer Focal Therapy
American Urological Association · 2026–2027
1593675
Sub-PI
Preserving Erectile Function by Quantifying the Nerve-Sparing step of the Robotic Prostatectomy (Deep Dissect)
National Cancer Institute · 2022–2027 · via Cedars-Sinai Medical Center· 2 renewals
R01CA273031-02
PI
Prostate Cancer Comparative Outcomes of New Conceptual Paradigms for Treatment (PC CONCEPT)
Patient-Centered Outcomes Research Institute · 2020–2027
PCORI CER-2019C1-15682
Co-I
PSMA/MR-guided Stereotactic Body Radiotherapy for High Risk Prostate Cancer
National Cancer Institute · 2020–2025
R01CA249615-02
PI
Defining prostate cancer oncologic outcomes after partial gland ablation
Urology Care Foundation · 2023–2025
UCF 228129-01

Completed grants (11)

PI
Evaluation of Transperineal Biopsy under Local Anesthesia, a Novel approach to Decrease Post-Biopsy Infections and Improve Cancer Detection
National Cancer Institute · 2020–2025
R01CA241758-05
PI
Characterization of mpMRI Features Associated with Persistence and Recurrence of Prostate Cancer After Partial Gland Ablation
New York Academy of Medicine · 2023–2024
NYAM 230131-01
PI
Data use agreement for outcomes of focal therapies for prostate cancer
Avenda Health, Inc. · 2019–2024
DUA 193365-01
KP
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
National Cancer Institute · 2017–2023
P50CA211024-05
PI
Development of a Nerve-Sparing Assessment Tool (N-SAT) to Optimize Erectile Function after Robot-Assisted Radical Prostatectomy
Urology Care Foundation · 2022–2023
UCF 222773-01
Co-I
Clinical and Translational Science Center - UL1
National Center for Advancing Translational Sciences · 2017–2022
UL1TR002384-01
PI
Focal Laser Ablation of Prostate Cancer using MR/US Fusion
NCI · 2017–2022 · via NIH RePORTER
R01CA218547-01
PI
Optimizing the Number and Location of Transperineal Systematic Prostate Biopsy Cores (The Ferdinand C. Valentine Medical Student Research Grants In Urology, PI is medical student Emily Cheng)
New York Academy of Medicine · 2021–2021
NYAM 212902-01
Co-I
Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JHCERSI)
United States Food & Drug Administration · 2019–2021 · via The Johns Hopkins University
U01FD005942-05
Sub-PI
Technology Diffusion in Cancer: Geographic Variations, Facilitators, Outcomes, and Costs
National Cancer Institute · 2016–2021 · via MD Anderson Cancer Center
R01CA207216-05
Sub-PI
San Antonio Center for Biomarkers of Risk for Prostate Cancer (SABOR)
National Cancer Institute · 2017–2020 · via University of Texas Health Science Center at San Antonio
U01CA086402-18

Clinical research

9

Active

2 studies

PI
Assessment of attitudes towards PSA screening and decision aids
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
PI
Clinical TrIAL of Approaches to Prostate cAncer suRgery
NA · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2023)
Prostate Cancer
NCT05155501

Completed & closed trials (7)

PI
Randomized Trial Comparing Transperineal vs. Transrectal MRI-targeted Prostate Biopsy; Randomized Controlled Trial Assessing Transperineal Prostate Biopsy to Reduce Infection Complications
NA · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
Infection
NCT04815876
PI
Evaluation of Acute Urinary Retention & Trial of Void Algorithm in the Prevention of CAUTI and Catheter Days
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
PI
Preserving Erectile Function by Quantifying the Nerve-Sparing Step of the Robotic Prostatectomy
Cedars-Sinai Medical Center · CLOSED TO ACCRUAL (as of 2024)
PI
Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for Treatment
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
Prostate Cancer
NCT04890314
PI
Evaluation of Transperineal Biopsy Under Local Anesthesia, a Novel Approach to Decrease Post-Biopsy Infections and Improve Cancer Detection
NA · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
Infection
NCT04843566
PI
Study of Prostate Ablation Related Energy Devices (SPARED) Registry
The Johns Hopkins University · IRB STUDY CLOSURE (as of 2022)
PI
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
PHASE3 · Janssen Research & Development, LLC · IRB STUDY CLOSURE (as of 2022)
Prostatic Neoplasms
NCT03767244

News mentions

4 View all WCM news ↗

New Prostate Biopsy Technique Lowers Infection Risk
September 19, 2024
A multi-institutional clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators showed that a newer technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches.
Less Prostate Cancer Screening Reduces Overdiagnosis but May Miss Aggressive Cases
April 22, 2022
Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer. Now, researchers from Weill Cornell Medicine have found that while these efforts have been effective, the incidence of higher-grade disease and metastasis at diagnosis have risen.
Commentary: Benefits of PSA Test for Prostate Cancer Substantially Greater than Generally Appreciated
June 17, 2020
The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, say investigators at Weill Cornell Medicine, NewYork-Presbyterian, University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center.
Weill Cornell Medicine Prostate Cancer Research Awarded Funding for Outcomes Studies
June 4, 2020
Dr. Jim Hu, the Ronald P. Lynch Professor of Urologic Oncology at Weill Cornell Medicine, has been awarded more than $7 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) for two studies on outcomes of prostate cancer biopsy and treatment.

Mentoring

5 All publications with mentees →